Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New cocktail aims to slow aggressive lung cancer

NCT ID NCT07373964

Disease control Sponsor: China Medical University, China Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new combination of drugs (chidamide, a PD-L1 inhibitor, carboplatin, and etoposide) as the first treatment for people with extensive-stage small-cell lung cancer, a fast-growing cancer that has spread. About 36 participants will receive the combination for 4 cycles, then continue chidamide alone to keep the cancer under control. The goal is to see if this approach delays cancer growth and is safe.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 36 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2025

Expected to finish

Oct 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥18 and ≤75 years. * Histologically confirmed ES-SCLC, unsuitable for local radical therapy. * No prior systemic therapy for ES-SCLC. * ECOG performance status 0-1. * At least one measurable lesion per RECIST v1.1. * Expected survival ≥3 months. * Adequate organ function (hematological, hepatic, renal, cardiac). * Effective contraception from consent until 180 days after last dose. * For active HBV infection: HBV DNA \<2000 IU/mL within 28 days before treatment and on stable antiviral therapy. * Recovery from prior therapy toxicities to ≤ Grade 1 (except alopecia). * Signed informed consent. Exclusion Criteria: * Factors significantly affecting oral drug absorption. * Prior HDAC inhibitor or immune checkpoint inhibitor therapy. * Known allergy to any study drug component. * Other malignancy within past 5 years (except certain cured cancers). * Participation in another clinical trial within 4 weeks. * Immunodeficiency, HIV positivity, or organ transplant history. * Uncontrolled cardiovascular disease or QTc \>450 ms. * Pregnancy, lactation, or unwillingness to use effective contraception. * Other severe comorbid conditions deemed unsafe by investigator. * History of neurological or psychiatric disorders. * Any condition making the patient unsuitable per investigator judgment.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Small cell lung cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Small cell lung cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • The First Affiliated Hospital of China Medical University

    RECRUITING

    Shenyang, Liaoning, 110001, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.